Epigallocatechin-3-gallate Suppresses Galactose-α1,4-galactose-β1,4-glucose Ceramide Expression in TNF-α Stimulated Human Intestinal Epithelial Cells Through Inhibition of MAPKs and NF-κB

Intestinal epithelial cells (IECs) have been known to produce galactose-α1,4-galactose-β1,4-glucose ceramide (Gb3) that play an important role in the mucosal immune response. The regulation of Gb3 is important to prevent tissue damage causing shiga like toxin. Epigallocatechin-3-gallate (EGCG) has been studied as anti-carcinogenic, anti-oxidant, anti-angiogenic, and anti-viral activities, and anti-diabetic. However, little is known between the expressions of Gb3 on IECs. The aim of this study was to examine the inhibitory effect of EGCG, a major ingredient of green tea, on Gb3 production via mitogen-activated protein kinases (MAPKs) and nuclear factor-kappa B (NF-κB) in the TNF-α stimulated human colon epithelial cells, HT29. To investigate how Gb3 is regulated, ceramide glucosyltransferase (CGT), lactosylceramide synthase (GalT2), and Gb3 synthase (GalT6) were analyzed by RT-PCR in HT 29 cells exposed to TNF-α in the presence or absence of EGCG. EGCG dose-dependently manner, inhibits TNF-α induced Gb3 expression by blocking in both the MAPKs and NF-κB pathways in HT29 cells. TNF-α enhanced CGT, GalT2 and GalT6 mRNA levels and EGCG suppressed the level of these enzymes enhanced by TNF-α treatment.